The inclusion of immunological biomarkers is increasingly recognized as important in the prediction of prognosis and response to cancer treatments. Classification of the host’s immune response to cancer, termed ‘immunoscore’, may add significant prognostic value over and above existing tumor classification systems. In an effort to promote use of the immunoscore in routine clinical settings, the SITC Immunoscore Validation Project was initiated with 23 centers in 17 countries worldwide. The results of this project may result in the implementation of the immunoscore as a new component for the classification of cancer.
2015 – Present
The Combination Immunotherapies Task Force has convened to: identify and prioritize the most important hypothesis-driven prospects for combination therapies; identify the key regulatory challenges in accelerating testing while maintaining a focus on patient safety; promote the development of safe, efficacious, and practical immunotherapeutic combinations through.